Status:
UNKNOWN
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Nonalcoholic Fatty Liver Disease (NAFLD)
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic effects of these two...
Detailed Description
Inclusion criteria: 18-70 years old patients who were diagnosed with mild-moderate hypertension and NAFLD; The patients did not take ACEIs or ARBs drugs six weeks before the inclusion; Patients agree...
Eligibility Criteria
Inclusion
- 18-70 years old patients who were diagnosed with mild-moderate hypertension and NAFLD;
- The patients did not take ACEIs or ARBs drugs six weeks before the inclusion; Patients agreed to participate in the trial and signed the informed consent.
Exclusion
- There are no coexisting causes for chronic liver disease, such as viral, alcoholic,drug-induced and autoimmune liver diseases;
- Patients with diabetes mellitus; Patients with serious primary diseases; Patients with mental disorder or can not take the medicine regularly;
- Pregnancy and nursing mothers;
- Allergic constitution or intolerance to ACEIs or ARBs drugs.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2017
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT02213224
Start Date
August 1 2014
End Date
September 1 2017
Last Update
August 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515